Surface testing for SARS-CoV-2 in hematology/oncology settings reveals negligible detection

Immunoglobulin clinical trial launched to prevent COVID-19 side effects
18 February 2021
Older adults and antibiotics: Study shows healthy attitudes but unhealthy practices
18 February 2021

Surface testing for SARS-CoV-2 in hematology/oncology settings reveals negligible detection

Researchers from Rutgers Cancer Institute of New Jersey, the state’s only National Cancer Institute-designated Comprehensive Cancer Center, evaluated the frequency of SARS-CoV-2, the virus that causes COVID-19, on various environmental surfaces in outpatient and inpatient hematology/oncology settings located within Rutgers Cancer Institute and Robert Wood Johnson University Hospital, an RWJBarnabas Health facility. The study revealed extremely low detection of SARS-CoV-2 on environmental surfaces across multiple outpatient and inpatient oncology areas, including an active COVID-19 floor. Andrew M. Evens, DO, MSc, FACP, associate director for clinical services and director of the Lymphoma Program at Rutgers Cancer Institute and medical director of the oncology service line at RWJBarnabas Health, is senior author of the work, which has been published in the February 18 online edition of Cancer.

Comments are closed.